Medpace Holdings Management
Management criteria checks 3/4
Medpace Holdings' CEO is August Troendle, appointed in Jul 1992, has a tenure of 33.58 years. total yearly compensation is $8.60M, comprised of 10.1% salary and 89.9% bonuses, including company stock and options. directly owns 18.95% of the company’s shares, worth $2.30B. The average tenure of the management team and the board of directors is 7 years and 7.5 years respectively.
Key information
August Troendle
Chief executive officer
US$8.6m
Total compensation
| CEO salary percentage | 10.07% |
| CEO tenure | 33.6yrs |
| CEO ownership | 19.0% |
| Management average tenure | 7yrs |
| Board average tenure | 7.5yrs |
Recent management updates
Recent updates
Medpace Holdings, Inc. (NASDAQ:MEDP) Just Reported, And Analysts Assigned A US$491 Price Target
Feb 13
Medpace Holdings: Great Quarter, Stale Backlog, Full Valuation
Feb 10Earnings Not Telling The Story For Medpace Holdings, Inc. (NASDAQ:MEDP) After Shares Rise 34%
Aug 11Medpace Holdings, Inc. Beat Revenue Forecasts By 12%: Here's What Analysts Are Forecasting Next
Jul 24Should You Think About Buying Medpace Holdings, Inc. (NASDAQ:MEDP) Now?
Jul 01Is Medpace Holdings, Inc. (NASDAQ:MEDP) Trading At A 48% Discount?
Jun 12Investor Optimism Abounds Medpace Holdings, Inc. (NASDAQ:MEDP) But Growth Is Lacking
May 08Medpace Holdings, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Apr 23Is Medpace Holdings, Inc. (NASDAQ:MEDP) Potentially Undervalued?
Mar 24Medpace: Impressive Revenue Growth, High ROE Values, And High Growth Potential
Feb 06Medpace: Buy The Short-Term Pain For Long-Term Gains
Oct 26Why Medpace Holdings Is A 'Better Mousetrap'
Oct 16
Temporary Setbacks Poised For A Swift Recovery And Strong Future Revenue Growth
Elevated project cancellations pose only a temporary risk, with potential for quick revenue and net new business awards recovery.Medpace: Continued Business Growth With Asymmetrical Payoff Opportunity
Aug 20Medpace: Clear Winner If China Blockade Succeeds
Jun 04Medpace: Exceptional Performance, Almost Fully Priced In
Mar 11CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | US$451m |
| Sep 30 2025 | n/a | n/a | US$433m |
| Jun 30 2025 | n/a | n/a | US$418m |
| Mar 31 2025 | n/a | n/a | US$416m |
| Dec 31 2024 | US$9m | US$866k | US$404m |
| Sep 30 2024 | n/a | n/a | US$366m |
| Jun 30 2024 | n/a | n/a | US$340m |
| Mar 31 2024 | n/a | n/a | US$312m |
| Dec 31 2023 | US$2m | US$814k | US$283m |
| Sep 30 2023 | n/a | n/a | US$273m |
| Jun 30 2023 | n/a | n/a | US$268m |
| Mar 31 2023 | n/a | n/a | US$257m |
| Dec 31 2022 | US$2m | US$770k | US$245m |
| Sep 30 2022 | n/a | n/a | US$227m |
| Jun 30 2022 | n/a | n/a | US$209m |
| Mar 31 2022 | n/a | n/a | US$199m |
| Dec 31 2021 | US$6m | US$697k | US$181m |
| Sep 30 2021 | n/a | n/a | US$182m |
| Jun 30 2021 | n/a | n/a | US$175m |
| Mar 31 2021 | n/a | n/a | US$159m |
| Dec 31 2020 | US$4m | US$608k | US$145m |
| Sep 30 2020 | n/a | n/a | US$124m |
| Jun 30 2020 | n/a | n/a | US$107m |
| Mar 31 2020 | n/a | n/a | US$110m |
| Dec 31 2019 | US$8m | US$504k | US$100m |
Compensation vs Market: August's total compensation ($USD8.60M) is below average for companies of similar size in the US market ($USD13.14M).
Compensation vs Earnings: August's compensation has increased by more than 20% in the past year.
CEO
August Troendle (69 yo)
Dr. August James Troendle, M.D. serves as Chairman of CinRx Pharma, LLC. He has been the Chairman, Chief Executive Officer at Medpace Holdings, Inc. since July 1992 and served as its President since July 1...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 33.6yrs | US$8.60m | 18.95% $ 2.3b | |
| President | 4.5yrs | US$4.71m | 0.053% $ 6.4m | |
| CFO & Treasurer | 7yrs | US$3.48m | 0.021% $ 2.5m | |
| Executive Vice President of Operations | 9.1yrs | US$4.83m | 0.21% $ 25.0m | |
| Chief Compliance Officer | 13.7yrs | US$3.70m | 0.047% $ 5.7m | |
| Chief Information Officer | 5.1yrs | no data | no data | |
| Associate Director of Investors Relations | no data | no data | no data | |
| Vice President of Business Development & Marketing | no data | no data | no data | |
| Senior Vice President of Biometrics | no data | no data | no data | |
| Senior Vice President of Commercial Operations & Clinical Pharmacology Unit | no data | no data | no data | |
| Chief Medical Officer of Medical Department | 3.1yrs | no data | no data | |
| Senior Vice President of Clinical Monitoring | no data | no data | no data |
Experienced Management: MEDP's management team is seasoned and experienced (7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 33.6yrs | US$8.60m | 18.95% $ 2.3b | |
| Lead Independent Director | 7.5yrs | US$264.92k | 0.019% $ 2.4m | |
| Independent Director | 7.5yrs | US$217.33k | 0.036% $ 4.4m | |
| Independent Director | 9.6yrs | US$227.34k | 0.0031% $ 380.4k | |
| Independent Director | 9.6yrs | US$234.65k | 0.12% $ 14.0m | |
| Independent Director | 3.1yrs | US$209.92k | 0% $ 0 | |
| Independent Director | 1.6yrs | US$161.50k | 0% $ 0 |
Experienced Board: MEDP's board of directors are considered experienced (7.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/18 23:03 |
| End of Day Share Price | 2026/02/18 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medpace Holdings, Inc. is covered by 19 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eric Coldwell | Baird |
| Luke Sergott | Barclays |
| Sean Dodge | BMO Capital Markets Equity Research |